ES2398381T3 - Conjugados del copolímero de ácido metacrílico-hpma-tnp-470 y sus usos - Google Patents

Conjugados del copolímero de ácido metacrílico-hpma-tnp-470 y sus usos Download PDF

Info

Publication number
ES2398381T3
ES2398381T3 ES03723958T ES03723958T ES2398381T3 ES 2398381 T3 ES2398381 T3 ES 2398381T3 ES 03723958 T ES03723958 T ES 03723958T ES 03723958 T ES03723958 T ES 03723958T ES 2398381 T3 ES2398381 T3 ES 2398381T3
Authority
ES
Spain
Prior art keywords
tnp
hpma
copolymer
polymer
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03723958T
Other languages
English (en)
Spanish (es)
Inventor
Ronit Satchi-Fainaro
Judah Folkman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Children's Hospital
Original Assignee
Boston Children's Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Children's Hospital filed Critical Boston Children's Hospital
Application granted granted Critical
Publication of ES2398381T3 publication Critical patent/ES2398381T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L53/00—Compositions of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Compositions of derivatives of such polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
    • C07D303/02—Compounds containing oxirane rings
    • C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
    • C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
    • C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
    • C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/56—Acrylamide; Methacrylamide
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F220/00—Copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical or a salt, anhydride ester, amide, imide or nitrile thereof
    • C08F220/02—Monocarboxylic acids having less than ten carbon atoms; Derivatives thereof
    • C08F220/52—Amides or imides
    • C08F220/54—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide
    • C08F220/58—Amides, e.g. N,N-dimethylacrylamide or N-isopropylacrylamide containing oxygen in addition to the carbonamido oxygen, e.g. N-methylolacrylamide, N-(meth)acryloylmorpholine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES03723958T 2002-04-11 2003-04-10 Conjugados del copolímero de ácido metacrílico-hpma-tnp-470 y sus usos Expired - Lifetime ES2398381T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US37179102P 2002-04-11 2002-04-11
US371791P 2002-04-11
US41470502P 2002-09-30 2002-09-30
US414705P 2002-09-30
PCT/US2003/010976 WO2003086382A1 (en) 2002-04-11 2003-04-10 Tnp-470 polymer conjugates and use thereof

Publications (1)

Publication Number Publication Date
ES2398381T3 true ES2398381T3 (es) 2013-03-15

Family

ID=29254460

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03723958T Expired - Lifetime ES2398381T3 (es) 2002-04-11 2003-04-10 Conjugados del copolímero de ácido metacrílico-hpma-tnp-470 y sus usos

Country Status (7)

Country Link
US (5) US7332523B2 (cg-RX-API-DMAC7.html)
EP (1) EP1494662B1 (cg-RX-API-DMAC7.html)
JP (1) JP4514455B2 (cg-RX-API-DMAC7.html)
AU (2) AU2003230852B2 (cg-RX-API-DMAC7.html)
CA (1) CA2480666C (cg-RX-API-DMAC7.html)
ES (1) ES2398381T3 (cg-RX-API-DMAC7.html)
WO (1) WO2003086382A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030100605A1 (en) * 2001-05-15 2003-05-29 Grupp Stephan A. Methods of treating cancer with angiogenesis inhibitors
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
JP4514455B2 (ja) * 2002-04-11 2010-07-28 チルドレンズ メディカル センター コーポレーション Tnp−470ポリマー複合体及びその使用
US20080248030A1 (en) * 2005-02-02 2008-10-09 Children's Medical Center Corporation Method of Treating Angiogenic Diseases
NZ560712A (en) * 2005-02-17 2010-12-24 Synta Pharmaceuticals Corp (3,4,5-trisubstituted-phenyl)isoxazole combretastin derivatives for the treatment of disorders
JP2010531896A (ja) 2007-06-26 2010-09-30 チルドレンズ メディカル センター コーポレーション 治療的投与のためのMetAP−2阻害剤ポリマーソーム
WO2009036108A1 (en) * 2007-09-13 2009-03-19 Children's Medical Center Corporation Methods and compositions for inhibiting vascular leakage
US9446150B2 (en) 2007-10-09 2016-09-20 Washington University Particles for imaging
WO2009049089A1 (en) 2007-10-09 2009-04-16 Washington University In St. Louis Ligand directed toroidal nanoparticles for therapy and diagnostic imaging
BRPI0820229A2 (pt) * 2007-11-28 2017-05-09 A Stevenson Cheri conjugados de análogos de fumagilina biodegradáveis biocompatíveis
WO2009141823A2 (en) 2008-05-22 2009-11-26 Ramot At Tel Aviv University Ltd. Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
EP2300021A4 (en) 2008-05-22 2014-10-08 Univ Ramot CONJUGATE OF A POLYMER, ANTI-ANGIOGENESE AGENT AND TARGETING REST, AND USES THEREOF FOR THE TREATMENT OF BONE-RELATED ANGIOGENESIS STATES
EP2307032A4 (en) * 2008-05-22 2014-08-20 Univ Ramot NEW CONJUGATES OF POLYMERS WITH A THERAPEUTIC AGENT AND AN ANGIOGENESIS TARGETING PART CONTAINED THEREOF, AND USES IN THE TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS
CA2768149A1 (en) * 2009-07-14 2011-01-20 Lucia Irene Gonzalez Stereoisomer peptides and their polymer conjugates for hiv disease
US8715986B2 (en) * 2009-10-29 2014-05-06 Lucia Irene Gonzalez Stereoisomer peptides, ligand-targeted multi- stereoisomer peptide polymer conjugates, and uses thereof
US9808500B2 (en) 2009-12-17 2017-11-07 Washington University Antithrombotic nanoparticle
US9764043B2 (en) 2009-12-17 2017-09-19 Washington University Antithrombotic nanoparticle
EP2558072B1 (en) 2010-04-15 2018-09-26 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
US20130137831A1 (en) * 2010-05-25 2013-05-30 John S. Petersen Optimized drug conjugates
US9895449B2 (en) 2010-05-25 2018-02-20 Syndevrx, Inc. Polymer-conjugated MetAP2 inhibitors, and therapeutic methods of use thereof
WO2011150022A2 (en) * 2010-05-25 2011-12-01 Syndevrx, Inc. Polymer-conjugated metap2 inhibitors, and therapeutic methods of use thereof
IN2014MN01819A (cg-RX-API-DMAC7.html) 2012-03-05 2015-07-03 Univ Ramot
EP3574922B1 (en) 2013-04-10 2021-09-15 Syndevrx, Inc. Modified or polymer-conjugated fumagillol metap2 inhibitors for use in improving or restoring insulin sensitivity
EP3020114B1 (en) 2013-07-11 2017-05-17 General Electric Company Grid power factor control system
TW201636342A (zh) 2014-12-19 2016-10-16 武田藥品工業有限公司 煙黴醇衍生物
KR102849342B1 (ko) 2015-12-10 2025-08-21 신데브알엑스, 인크. 푸마길롤 유도체 및 그의 다형체
AU2017206718B2 (en) 2016-01-11 2021-09-30 Syndevrx, Inc. Treatment for tumors driven by metabolic dysfunction
KR20200096939A (ko) * 2017-12-06 2020-08-14 제넨테크, 인크. 면역조직화학을 위한 합성 대조군
US11612577B2 (en) 2018-10-26 2023-03-28 Syndevrx, Inc. Biomarkers of METAP2 inhibitors and applications thereof

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8500209D0 (en) * 1985-01-04 1985-02-13 Ceskoslovenska Akademie Ved Synthetic polymeric drugs
US5164410A (en) * 1988-01-09 1992-11-17 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
EP0359036B1 (en) * 1988-09-01 1997-03-26 Takeda Chemical Industries, Ltd. Fumagillol derivatives
US5180738A (en) * 1988-09-01 1993-01-19 Takeda Chemical Industries Fumagillol derivatives and pharmaceutical compositions thereof
US5166172A (en) * 1988-09-01 1992-11-24 Takeda Chemical Industries, Ltd. Fumagillol derivatives and pharmaceutical compositions thereof
US5290807A (en) * 1989-08-10 1994-03-01 Children's Medical Center Corporation Method for regressing angiogenesis using o-substituted fumagillol derivatives
US6017954A (en) * 1989-08-10 2000-01-25 Children's Medical Center Corp. Method of treating tumors using O-substituted fumagillol derivatives
EP0415294A3 (en) * 1989-08-31 1991-06-12 Takeda Chemical Industries, Ltd. Cyclohexanol derivatives, production and use thereof
DE69714230T2 (de) * 1996-03-06 2003-03-27 Tsumura & Co., Tokio/Tokyo Neue iridoidderivate und neovaskularisations-inhibitoren die diese als aktviven inhaltstoff enthalten
US6225478B1 (en) * 1997-03-05 2001-05-01 Tsumura & Co. Iridoid derivatives and neovascularization inhibitors containing the same as active ingredient
AU1820400A (en) 1999-11-17 2001-05-30 School Of Pharmacy, University Of London, The Conjugates of hpma copolymer and ellipticin
WO2001097776A1 (fr) 2000-06-22 2001-12-27 Takeda Chemical Industries, Ltd. Composition médicamenteuse contenant un polymère
ATE552859T1 (de) * 2000-09-13 2012-04-15 Praecis Pharm Inc Pharmazeutische formulierungen zur kontinuierlichen abgabe von peptiden
EP1330447A2 (en) * 2000-11-01 2003-07-30 Praecis Pharmaceuticals Incorporated Peptides as met-ap2 inhibitors
US6548477B1 (en) * 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6919307B2 (en) 2000-11-01 2005-07-19 Praecis Pharmaceuticals, Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
US6858580B2 (en) 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
JP4514455B2 (ja) * 2002-04-11 2010-07-28 チルドレンズ メディカル センター コーポレーション Tnp−470ポリマー複合体及びその使用
CA2480809A1 (en) * 2002-04-11 2003-10-23 Children's Medical Center Corporation Methods for inhibiting vascular hyperpermeability
KR20060130077A (ko) * 2003-12-29 2006-12-18 프래시스 파마슈티컬즈 인코포레이티드 메티오닌 아미노펩티다제-2 의 저해제 및 이의 용도

Also Published As

Publication number Publication date
US6949584B2 (en) 2005-09-27
US20060020024A1 (en) 2006-01-26
AU2003230852A1 (en) 2003-10-27
WO2003086382A1 (en) 2003-10-23
AU2008229857A1 (en) 2008-10-30
AU2003230852B2 (en) 2008-07-10
US20080112919A1 (en) 2008-05-15
US7332523B2 (en) 2008-02-19
CA2480666A1 (en) 2003-10-23
JP2005529870A (ja) 2005-10-06
EP1494662B1 (en) 2012-11-28
EP1494662A4 (en) 2006-07-19
EP1494662A1 (en) 2005-01-12
US20090176874A1 (en) 2009-07-09
US20040229945A1 (en) 2004-11-18
JP4514455B2 (ja) 2010-07-28
CA2480666C (en) 2012-03-06
US20050169881A1 (en) 2005-08-04

Similar Documents

Publication Publication Date Title
EP1494662B1 (en) Tnp-470-hpma-methacrylic acid copolymer conjugates and use thereof
Chytil et al. HPMA copolymer–drug conjugates with controlled tumor‐specific drug release
Satchi-Fainaro et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
US20080248030A1 (en) Method of Treating Angiogenic Diseases
Iyer et al. Exploiting the enhanced permeability and retention effect for tumor targeting
Yang et al. Treatment of prostate carcinoma with (galectin-3)-targeted HPMA copolymer-(G3-C12)-5-Fluorouracil conjugates
CN102105157B (zh) 聚合物、抗血管生成剂和靶向部分的缀合物及其在制备用于治疗骨相关血管生成状况的药物中的用途
KR20150001710A (ko) In Vivo 핵산 전달용 폴리(아크릴레이트) 고분자
JP2010163468A (ja) ポリリンゴ酸ベースの多機能性薬物送達システム
US8795648B2 (en) Poly(beta malic acid) with pendant Leu-Leu-Leu tripeptide for effective cytoplasmic drug delivery
US20140134111A1 (en) Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases
AU2018342909A1 (en) Castration resistant prostate cancer
CN109475637A (zh) 可切割的聚合物药物偶联物
Tsukigawa et al. Effect of different chemical bonds in pegylation of zinc protoporphyrin that affects drug release, intracellular uptake, and therapeutic effect in the tumor
Etrych et al. Comparison of the pharmacological and biological properties of HPMA copolymer-pirarubicin conjugates: A single-chain copolymer conjugate and its biodegradable tandem-diblock copolymer conjugate
Zhou et al. Combination therapy of prostate cancer with HPMA copolymer conjugates containing PI3K/mTOR inhibitor and docetaxel
CZ200985A3 (cs) Polymerní konjugáty paclitaxelu a docetaxelu s pH rízeným uvolnováním kancerostatika
Wei et al. Disulfide bonds as a molecular switch of enzyme-activatable anticancer drug precise release for fluorescence imaging and enhancing tumor therapy
WO2020218390A1 (ja) 結合体、及び癌治療剤
Hanahan ll, 2002, provisional application No. 60/414.705, Antoine, N. et al., AGM-1470, a potent angiogenesis inhibitor. filed on Sep. 30, 2002. prevents the entry of normal but not transformed endothelial cells
Kavitha et al. Polyacrylamide and related polymers
Ofek et al. Rational design of multifunctional polymer therapeutics for cancer theranostics
Clementi Studies on polymer conjugation as versatile tool for drug delivery
HK1220397B (en) Polyconjugates for delivery of rnai triggers to tumor cells in vivo
HK1220397A1 (zh) 用於在活体中递送rnai触发子至肿瘤细胞的聚偶联物